A team at the National Health Research Institutes (NHRI) has discovered a novel orally available small molecule, DBPR728, that can cut off the nutrient supply for cancer cell growth, which can serve as a new targeted therapy drug.
The research team consists of scientists from the NHRI’s Institute of Biotechnology and Pharmaceutical Research, including Chi Ya-hui (紀雅惠), Yeh Teng-kuang (葉燈光), Chen Chiung-tong (陳炯東) and Chang Chun-ping (張竣評).
Chi told a news conference at the Ministry of Health and Welfare in Taipei yesterday that the occurrence of cancer is often caused by genetic aberrations that lead to uncontrolled cell proliferation.
Photo: Chen Yi-kuan, Taipei Times
An “oncogene” is a gene that has the potential to transform normal cells into cancerous ones through genetic aberrations — including mutation, fusion and amplification, she said.
Genetic amplification refers to an increase in the number of copies of the same gene, and studies have suggested that approximately 28 percent of cancers exhibit Myelocytomatosis (MYC) oncogene amplification, Chi said, adding that they include lung cancer, breast cancer, liver cancer and prostate cancer, as well as several other types.
For cancer cells to grow, the MYC oncoprotein functions as a transcription factor, facilitating the production of enzymes required for glycolysis (the process of breaking down glucose to produce energy), she said.
Therefore, MYC overexpression (too many copies of the MYC oncoprotein) allows cancer cells to metabolize energy in low-oxygen conditions, leading to uncontrolled cell growth and high post-operative recurrence rates, ultimately reducing overall patient survival rates, she said.
However, while there are many therapies that target specific genetic mutations in cancer cells, there are still challenges in developing drugs that target several oncogenes and their cancer-driving proteins, such as the MYC oncogene, due to the intrinsic properties of its proteins, Chi said.
In an effort to suppress MYC overexpression, Chi said the team tried to exploit its “good friend,” the enzyme Aurora kinase A, which stabilizes the MYC protein, by designing small molecules that disrupt the interaction between the two proteins, leading to MYC protein degradation.
They used the molecule DBPR728 to create an inactive oral drug that is stable in the gastrointestinal tract and can be bioconverted to become active when it reaches tumor cells, she said.
Chi said administering the oral drug to mice which have tumor cells with MYC genetic amplification and overexpression showed that the drug to can efficiently induce MYC reduction and cell apoptosis (the process of programmed cell death) in just 10 days.
The drug has obtained a patent in Taiwan and the team is applying for patents in other nations, and hopefully after it passes preclinical toxicity studies and clinical trials, it can be produced as a targeted drug for cancer treatment, she said.
The team’s findings were published in the June issue of Molecular Cancer Therapeutics, a leading journal published by the American Association for Cancer Research.
Two US House of Representatives committees yesterday condemned China’s attempt to orchestrate a crash involving Vice President Hsiao Bi-khim’s (蕭美琴) car when she visited the Czech Republic last year as vice president-elect. Czech local media in March last year reported that a Chinese diplomat had run a red light while following Hsiao’s car from the airport, and Czech intelligence last week told local media that Chinese diplomats and agents had also planned to stage a demonstrative car collision. Hsiao on Saturday shared a Reuters news report on the incident through her account on social media platform X and wrote: “I
SHIFT PRIORITIES: The US should first help Taiwan respond to actions China is already taking, instead of focusing too heavily on deterring a large-scale invasion, an expert said US Air Force leaders on Thursday voiced concerns about the Chinese People’s Liberation Army’s (PLA) missile capabilities and its development of a “kill web,” and said that the US Department of Defense’s budget request for next year prioritizes bolstering defenses in the Indo-Pacific region due to the increasing threat posed by China. US experts said that a full-scale Chinese invasion of Taiwan is risky and unlikely, with Beijing more likely to pursue coercive tactics such as political warfare or blockades to achieve its goals. Senior air force and US Space Force leaders, including US Secretary of the Air Force Troy Meink and
‘BUILDING PARTNERSHIPS’: The US military’s aim is to continue to make any potential Chinese invasion more difficult than it already is, US General Ronald Clark said The likelihood of China invading Taiwan without contest is “very, very small” because the Taiwan Strait is under constant surveillance by multiple countries, a US general has said. General Ronald Clark, commanding officer of US Army Pacific (USARPAC), the US Army’s largest service component command, made the remarks during a dialogue hosted on Friday by Washington-based think tank the Center for Strategic and International Studies. Asked by the event host what the Chinese military has learned from its US counterpart over the years, Clark said that the first lesson is that the skill and will of US service members are “unmatched.” The second
Czech officials have confirmed that Chinese agents surveilled Vice President Hsiao Bi-khim (蕭美琴) during her visit to Prague in March 2024 and planned a collision with her car as part of an “unprecedented” provocation by Beijing in Europe. Czech Military Intelligence learned that their Chinese counterparts attempted to create conditions to carry out a demonstrative incident involving Hsiao, which “did not go beyond the preparation stage,” agency director Petr Bartovsky told Czech Radio in a report yesterday. In addition, a Chinese diplomat ran a red light to maintain surveillance of the Taiwanese
RSS